U.S. markets closed

Clinuvel Pharmaceuticals Limited (CLVLY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
21.480.00 (0.00%)
At close: 3:08PM EDT

Clinuvel Pharmaceuticals Limited

535 Bourke Street
Level 11
Melbourne, VIC 3000
Australia
61 3 9660 4900
http://www.clinuvel.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Philippe Jacques Wolgen M.B.A., MBA, M.D.CEO, MD & Director1.27MN/A1963
Mr. Darren M. KeamyCFO & Company Sec.274.13kN/A1973
Dr. Dennis J. WrightChief Scientific Officer218.63kN/AN/A
Mr. Malcolm BullHead of Investor RelationsN/AN/AN/A
Lachlan HayGen. Mang. of EuropeN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Corporate Governance

Clinuvel Pharmaceuticals Limited’s ISS Governance QualityScore as of July 1, 2021 is 8. The pillar scores are Audit: 9; Board: 5; Shareholder Rights: 10; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.